Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
What is your preferred dose and schedule for maintenance drugs post autoHCT for newly diagnosed multiple myeloma?
Related Questions
What is your approach to bone imaging in MGUS?
In a patient with cardiac light chain amyloid who has significant heart failure symptoms, including inotrope dependence at presentation, how much clinical benefit does treatment provide?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
How do you approach the second-line treatment for a patient with high-risk myeloma relapse early post-autoHCT after Dara-RVD induction?
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?
Does treating CLL reduce the risk of non-melanoma skin cancers?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
